Catalyst earns $2.1M milestone as Japan approves FIRDAPSE for LEMS

CATALYST PHARMACEUTICALS, INC.

Japan's Ministry of Health approved DyDo's NDA for FIRDAPSE (amifampridine) 10 mg to treat Lambert-Eaton myasthenic syndrome (LEMS).
Catalyst receives JPY 300 million (~$2.1M) milestone payment from sub-licensee DyDo upon approval.
FIRDAPSE is the only FDA-approved LEMS treatment in the U.S.; approval expands access to Japan.
Catalyst CEO says approval underscores commitment to expanding rare disease product portfolio beyond the U.S.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.